Abstract | BACKGROUND AND AIMS: METHODS: Retrospective chart review was performed of 88 IBD patients at our center between 2010 and 2013. Low-dose MTX was defined as ≤ 12.5mg/week and high-dose MTX as 15-25mg/week. Patients who met the criteria for clinical remission [Harvey-Bradshaw Index ≤ 4, Simple Clinical Colitis Activity Index ≤ 2] at baseline were followed for up to 42 months. Chart review occurred in 6-month intervals. The primary outcome was consecutive months in remission prior to relapse. Secondary outcomes included other indicators of worsening disease [endoscopic inflammation, steroid use, therapy escalation/addition, or surgery] and adverse events. Regression analysis and Kaplan-Meier survival analysis were completed. RESULTS: We identified 73 [83%] dual- therapy patients, of whom 32 low-dose and 14 high-dose individuals achieved remission. When compared with high-dose patients, low-dose patients were more likely to relapse [log-rank test, p < 0.01]. Secondary indicators of worsening disease occurred during 34.4% of low-dose review periods and 31.4% of high-dose review periods [p = 0.67]; 3/52 [6%] low-dose patients and 3/21 [14%] high-dose patients [p = 0.34] discontinued MTX therapy due to adverse events. CONCLUSIONS: When combined with anti-TNF therapy, MTX at doses of >12.5mg/week was more effective at maintaining clinical remission than lower doses. These findings will guide management of combination therapy in IBD patients.
|
Authors | Ruben J Colman, David T Rubin |
Journal | Journal of Crohn's & colitis
(J Crohns Colitis)
Vol. 9
Issue 4
Pg. 312-7
(Apr 2015)
ISSN: 1876-4479 [Electronic] England |
PMID | 25616487
(Publication Type: Journal Article, Research Support, N.I.H., Extramural)
|
Copyright | Copyright © 2015 European Crohn’s and Colitis Organisation (ECCO). Published by Oxford University Press. All rights reserved. For permissions, please email: [email protected]. |
Chemical References |
- Anti-Inflammatory Agents
- Gastrointestinal Agents
- Immunosuppressive Agents
- Tumor Necrosis Factor-alpha
- Infliximab
- Adalimumab
- Methotrexate
|
Topics |
- Adalimumab
(administration & dosage)
- Adolescent
- Adult
- Anti-Inflammatory Agents
(administration & dosage)
- Dose-Response Relationship, Drug
- Drug Therapy, Combination
- Female
- Follow-Up Studies
- Gastrointestinal Agents
(administration & dosage)
- Humans
- Immunosuppressive Agents
(administration & dosage)
- Inflammatory Bowel Diseases
(drug therapy)
- Infliximab
(administration & dosage)
- Male
- Methotrexate
(administration & dosage)
- Middle Aged
- Remission Induction
- Retrospective Studies
- Treatment Outcome
- Tumor Necrosis Factor-alpha
(antagonists & inhibitors)
- Young Adult
|